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Abstract To study the sensitivity of laser flare
photometry (LFP) in monitoring anterior chamber
inflammation by correlating LFP measurements with
slit-lamp evaluation of aqueous cells in HLA-B27-
related uveitis in a prospective trial. Slit-lamp cell
evaluation was correlated with LFP-measured flare in
a masked fashion in HLA-B27-related uveitis patients
receiving standard topical therapy. At the time of 50
and 90% LFP flare reduction, the corresponding
reduction of cells was recorded and statistically
compared using the sign test. Forty-three episodes
(in 43 patients) of acute anterior HLA-B27-related
uveitis were included. LFP flare reduction and slit-
lamp cell reduction were strongly correlated. LFP
was significantly more sensitive for both 50% (P =
0.001) and 90% (P = 0.02) LFP flare reduction in
assessing the decrease of anterior chamber inflam-
mation. LFP was superior to slit-lamp cell evaluation
in monitoring anterior chamber inflammation in
uveitis. Flare, becoming a quantitative parameter
when measured by LFP, rather than cells, should be
considered the gold standard to measure anterior
chamber inflammation in uveitis.
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Introduction
In 1959, a standardization system for the evaluation
of intra-ocular inflammatory activity in uveitis was
established and has been almost universally used for
more than 40 years [1, 2]. In 2004 a panel of uveitis
specialists that convened to establish new universal
criteria for the standardization of uveitis nomencla-
ture (SUN) re-adopted this grading system essentially
unchanged despite the fact that laser flare photometry
(LFP), a precise new technology for the grading of
intra-ocular inflammation had been available for
The results presented here apply only to slit-lamp models of
flaremeters (Kowa FC-1000, Kowa FC-2000 and Kowa
FM-500), but cannot be extrapolated to the FM-600 model
which is ill-suited for use in uveitis.
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more than 20 years [3]. Despite these efforts of
standardization, the assessment of inflammation
(aqueous cells and flare) still remains subjective with
large intra-observer and inter-observer variations.
Aqueous flare and cells are the most useful param-
eters to evaluate the progression or regression of
inflammation in the anterior segment. Because ante-
rior chamber cells could be quantified to a certain
extent, this was considered by uveitis specialists to be
the predominant parameter in anterior inflammation
[4]. Flare was considered less useful because it could
not be evaluated as accurately as cells. The slit-lamp
assessment of both flare and cells in the aqueous
humor is based on the same optical principle of
recording back-scattered light particles (photons)
from a light beam directed into the anterior
chamber [5].
LFP, a new technology commercially available
since 1989, is based on the same principle as slit-
lamp flare evaluation, measuring back-scattered light
from protein particles in the anterior chamber [6]. It
differs, however, from slit-lamp flare evaluation in
several crucial aspects. The light source (incoming
light) in LFP is a laser beam, by definition mono-
chromatic, emitting a constant quantity of photons
over time, whereas the incoming light in slit-lamp
flare evaluation is polychromatic and subject to
fluctuations. In slit-lamp flare evaluation the detector
is the human eye and the data are analyzed by the
human brain, whereas in LFP the detector is a
photodetector/photomultiplier and the data are ana-
lyzed by a computer [6]. This represents a tremen-
dous gain of sensitivity, making flare the only
inflammatory parameter that can be quantified to
date. The extent of sensitivity gain over the classic
slit-lamp flare evaluation becomes evident when
considering the two scales. A scale ranging from
1–4 in slit-lamp flare evaluation compared to a scale
ranging from 4 photons/millisecond (ph/ms, the nor-
mal flare value in a non-inflamed eye) to values as
high as 1000 ph/ms in LFP indicates the difference of
sensitivities [7]. Precise follow-up of inflammation is
now possible not only for flare levels that are
clinically apparent but also in low or subclinical
flare states on one side and very high flare states on
the other side; two situations where the human eye is
absolutely unable to measure flare variations [8].
LFP has become the standard method in evaluating
post-surgical anti-inflammatory therapy such as in
post-cataract inflammation [9–11]. It has also been
shown to be reliable in monitoring therapy and
predicting inflammatory recurrences in posterior
uveitis when a sufficient level of associated blood–
aqueous barrier disruption (flare) is present [12].
In this prospective masked trial the purpose was to
compare the sensitivity of LFP in detecting changes
in inflammation level in comparison to aqueous cell
determination by slit-lamp examination and thereby
to establish the accuracy, the superiority as compared
to slit-lamp cell analysis, and the reliability and
consistency of LFP for the determination, grading
and follow-up of inflammation in acute anterior
HLA-B27-related uveitis
Patients and methods
Patients known to be HLA B27-positive who were
seen for a recurrent episode of inflammation, who had
not been on therapy and had been asymptomatic for
more than two months, or patients who presented
with a first episode of non-granulomatous anterior
uveitis of sudden onset that tested positive for the
HLA B27 antigen, seen in the uveitis clinic of Hoˆpital
Jules Gonin and in the Centre for Ophthalmic
Specialised Ophthalmic Care (COS), were included
in the study.
The study was approved by the local IRB and the
patient’s consent was obtained according to the
Declaration of Helsinki.
Patients were evaluated clinically and by LFP at
presentation and on days D1, D2–4, D7, D14, D21,
D28 and on months M2 and M6.
Clinical evaluation
The clinical evaluation was performed by a clinician
who was not aware of the LFP measurements.
Specific clinical items were evaluated. Symptoms
including photophobia and pain were graded from 0
to 3. Best-corrected visual acuity (BCVA) was
measured.
Slit-lamp examination comprised the evaluation of
conjunctival hyperhemia, graded from 0 to 3. Flare
was graded from 0treit slit-lamp with a slit-lamp
beam ± 3 mm length and 1 mm width (0 = com-
plete absence of flare; 1 = faint flare, barely detect-
able flare; 2 = moderate flare, iris and lens details
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clear; 3 = marked flare, iris and lens details hazy;
4 = intense flare, fixed, coagulated aqueous humor
with fibrin). Using the same beam parameters,
aqueous cells were graded from to 4 (0 = no cells;
rare = cells found with prolonged viewing; occa-
sional = 1–4 cells per field; 1 = 5–10 cells per field;
2 = 11–20 cells per field; 3 = 21–50 cells per field;
4 = [50 cells per field).
The following additional signs were looked for:
fibrin, keratic precipitates (KPs) (mutton fat KPs,
when present, were an exclusion criterion), synech-
iae, graded from 0 to 4, according to the number of
quadrants involved and nodules (Koeppe and Bus-
acca nodules, when present, were also an exclusion
criterion).
Measurement of intra-ocular inflammation
by LFP
Anterior chamber flare was measured by a masked
investigator who was unaware of the clinical findings
using a laser flare cell meter FC 1000 or the laser flare
meter FM-500 (Kowa Co, Tokyo, Japan). The
instrument consists of a He–Ne or a diode laser, a
photomultiplier and an analyzing unit. The laser
beam, aimed into the anterior chamber, produces
scattering of photons when proteins or particles are
present [12–14]. The anterior chamber, isolated by
the hemato-ocular barrier, is normally practically free
of proteins and flare values measured with the LFP
are very low, at a level of 4 ph/ms. In the case of
inflammation there is a rupture of this barrier with an
influx of proteins and inflammatory cells which are
measured in a determined window [13–15]. Every
LFP examination included nine measurements. The
two highest and the two lowest values were discarded
giving a measurement average using five measure-
ments. The LFP measurements were not available to
the clinician and were recorded on a separate sheet.
Therapeutical protocol
At presentation the patients were dilated using
phenylephrine 5%, tropicamide 1% and scopolamine
0.25% drops in association with prednisolone acetate
1% drops (Pred Forte), one drop every 5 min
(3 cycles). Thereafter, hourly prednisolone acetate
1% drops were prescribed from 07:00 to 23:00 and
prednisolone 0.5% ointment was used at night.
Dilatation was maintained using scopolamine 0.25%
t.i.d. Tapering was based on AC cells following a
precisely established treatment schedule. In the case
of new fibrin formation after D0, occurrence of a
hypopyon or occurrence of new synechiae, a peri-
ocular injection of bethamethasone (4%) was given in
addition to the topical treatment.
Statistical methods
For each patient, the time required to reach a specific
reduction of the LFP value, namely a 50 or 90% gain,
was recorded. In a simplified approach, we noted the
first examination at which such a gain was observed.
Because of the large scatter of inflammation levels,
the non-parametric sign test was then used to
establish whether the corresponding reduction of
aqueous cells evaluated by slit-lamp examination was
significantly higher or lower.
In a second approach by interpolation between
examinations, the mean time to reach a 50 or 90%
reduction for both LFP-evaluated flare and aqueous
cell was estimated in order to provide a rough
estimate of the time advantage of one measurement
method over the other.
Results
Forty-three patients presenting with an episode of
acute anterior HLA-B27-related uveitis were included.
The mean age of the collective was 44 ± 12 years and
included 30 male and 13 female patients.
The numerical values of the main parameters,
LFP-evaluated flare, slit-lamp-evaluated flare and
cells, visual acuity and IOP were recorded at
presentation and on the follow-up visits and are
shown in Table 1.
The evolution over time of LFP-measured flare
values and of slit-lamp-evaluated aqueous cells are
seen in Figs. 1 and 2. LFP flare reduction and
slit-lamp cell reduction were strongly correlated
(P = 0.9). The interpolated mean time for a 50%
LFP flare reduction and aqueous cell reduction was
3.9 and 14 days, respectively. The 90% reduction
time was 19.6 days for LFP flare and 40 days for slit-
lamp-evaluated aqueous cells showing a much higher
sensitivity for LFP flare in assessing the evolution of
the decrease of inflammation.
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The sensitivities of LFP and slit-lamp cell evalu-
ation in assessing the reduction of inflammation are
seen in Figs. 3 and 4. For both the 50% and 90% LFP
flare reduction, LFP was significantly more sensitive
than slit-lamp cells in assessing evolution of anterior
chamber inflammation than slit-lamp evaluation of
aqueous cells (P \ 0.0001 and P \ 0.02). This
means that for each patient reaching a 50% and
90% reduction of LFP flare the corresponding
reduction of slit-lamp cells was noted, showing that
LFP flare reduction was significantly more important
than the reduction of cells.
Discussion
LFP has been shown to be superior to slit-lamp flare
evaluation and to slit-lamp aqueous cell evaluation in
traumatic (post-surgical, post-laser) inflammation and
has been shown to be superior to slit-lamp flare
evaluation in immunogenic (uveitic) inflammation
[7, 9–12, 16]. In uveitis there is still a tendency to
consider slit-lamp evaluation of aqueous cells as the
gold standard for determining and monitoring ante-
rior chamber inflammation. In this study our primary
aim was to compare the accuracies of LFP-deter-
mined flare and slit-lamp evaluation of aqueous cells
in assessing anterior chamber inflammation and to
determine the superiority of this new quantitative
method over classical slit-lamp cell evaluation of
inflammation in uveitis patients. We therefore did not
focus in the presentation of our results on the clinical
Table 1 Mean LFP flare, slit-lamp flare and slit-lamp cells, best-corrected visual acuity (BCVA) and intra-ocular pressure (IOP) on
the different measurement days
D0 D1 D2 - D4 D7 D14 D21 M2 M6
LFP flare 143 ± 23.9 101.8 ± 29 83.7 ± 21.2 51.7 ± 13.7 22.5 ± 4.2 15.7 ± 2.5 7.64 ± 0.7 5.03 ± 0.33
SL flare 2.28 2.0 1.42 1.07 0.77 0.58 0.16 0.014
SL cells 2.52 2.48 2.09 1.47 0.75 0.55 0.08 0
BCVA 0.9 0.77 0.87 0.92 0.97 1.05 1.13 1.2
IOP 12.2 11.9 13.7 13.0 13.0 12.8 14.8 14.1
Fig. 1 Evolution of mean LFP flare ± SD over time
Fig. 2 Evolution of mean cell count ± SD over time
Fig. 3 Correlation between LFPflare reduction and slit-lamp
cell reduction at 50% LFP reduction time. Each circle
represents one episode at 50% LFP flare reduction. A great
majority of cases have a 50% flare reduction on or before D7.
At this moment there is not yet a 50% cell reduction in the
majority of episodes (most circles are above the 50% cell
reduction line)
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and laser flare photometric profile of acute anterior
HLA-B27-related uveitis that was determined in
previous studies [16, 17]. The mean initial LFP flare
and its evolution were comparable to our previous
study, as were the final flare, mean duration of an
episode and the clinical characteristics [16, 17]. Our
data establish statistically for the first time that
aqueous flare, when measured by LFP, is a more
sensitive parameter than aqueous cells in assessing
and following intra-ocular inflammation. The method
is markedly more sensitive up to day seven of an
episode when considering the 50% flare reduction
and up to day 21 of an episode when considering the
90% flare reduction. The time advantage of LFP over
slit-lamp cell evaluation is considerable as the mean
time for a 50% reduction is 3.9 days for LFP flare and
14 days for cells. A 90% reduction is reached after
19.6 days for LFP flare and after 40 days for cells.
We chose a very specific and well-determined type of
uveitis to assess this new technology in uveitis. These
results, however, can be extrapolated to any uveitis-
producing inflammation in the anterior segment with
the only exception of chronic blood–aqueous barrier
disruption. Recently LFP flare profiles have been
studied in panuveitis entities including Behc¸et’s
uveitis and Vogt–Koyanagi–Harada disease, showing
persistence of slight elevation of LFP flare indicating
persistent blood–ocular barrier disruption [18, 19].
This is the same in our study as shown by the graph
of 90% flare reduction. While cells are resorbed, it
takes time for the blood–ocular barrier to completely
restore itself after severe inflammation, a fact that
could not been found without LFP.
Although LFP is still able to measure additional
new inflammation in these cases, the assessement of
aqueous cells is still useful in monitoring intra-ocular
inflammation. The certainty of having a quantitative,
accurate and reliable method to assess even slight
changes in intra-ocular inflammation will add security
in the follow-up of inflammatory cases and should be
considered the method of reference to measure intra-
ocular inflammation. This is not only the case for acute
inflammation such as HLA-B27-related uveitis but
also in chronic inflammation such as uveitis related to
idiopathic juvenile arthritis especially when there are
no cells. We have shown that, even in the absence of
cells, flare could be reduced with maximal therapy
indicating that there can be active inflammation
without the presence of cells [20]. LFP will not
determine decision–making by itself but will contrib-
ute, together with clinical examination and other
paraclinical tests such as fluorescein and indocyanine
green angiography, when indicated, to a more accurate
management of uveitis patients.
In conclusion, LFP was shown to be superior to
slit-lamp cell evaluation in monitoring intra-ocular
inflammation. By becoming a quantitative and objec-
tive parameter, when measured by LFP, flare rather
than aqueous cells should be considered the reference
parameter to monitor anterior chamber inflammation.
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